INKON Life Technology Co Ltd Net Assets
INKON Life Technology Co Ltd net assets. Based on the latest financial reports, INKON Life Technology Co Ltd (300143) has net assets worth CN¥2.65 Billion CNY (≈ $387.82 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥4.17 Billion ≈ $610.67 Million USD) and total liabilities (CN¥1.52 Billion ≈ $222.85 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore net asset growth rate of INKON Life Technology Co Ltd to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.65 Billion |
| % of Total Assets | 63.51% |
| Annual Growth Rate | 21.82% |
| 5-Year Change | 44.91% |
| 10-Year Change | 19.16% |
| Growth Volatility | 139.37 |
Net Assets of INKON Life Technology Co Ltd (2007–2025)
Net assets of INKON Life Technology Co Ltd from 2007 to 2025. This chart illustrates how INKON Life Technology Co Ltd's net assets have evolved over time, based on quarterly financial data. See net asset quality index of INKON Life Technology Co Ltd to measure how much of total assets are equity-financed.
Annual Net Assets for INKON Life Technology Co Ltd (2007–2025)
The table below shows the annual net assets of INKON Life Technology Co Ltd from 2007 to 2025. For live market cap and overall valuation, see how much is INKON Life Technology Co Ltd worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.62 Billion ≈ $382.85 Million |
+5.57% |
| 2024-12-31 | CN¥2.48 Billion ≈ $362.66 Million |
+73.45% |
| 2023-12-31 | CN¥1.43 Billion ≈ $209.08 Million |
+8.46% |
| 2022-12-31 | CN¥1.32 Billion ≈ $192.77 Million |
-27.04% |
| 2021-12-31 | CN¥1.81 Billion ≈ $264.20 Million |
-19.42% |
| 2020-12-31 | CN¥2.24 Billion ≈ $327.88 Million |
+63.86% |
| 2019-12-31 | CN¥1.37 Billion ≈ $200.10 Million |
-33.85% |
| 2018-12-31 | CN¥2.07 Billion ≈ $302.49 Million |
-15.02% |
| 2017-12-31 | CN¥2.43 Billion ≈ $355.97 Million |
+10.79% |
| 2016-12-31 | CN¥2.20 Billion ≈ $321.31 Million |
+47.95% |
| 2015-12-31 | CN¥1.48 Billion ≈ $217.17 Million |
+331.47% |
| 2014-12-31 | CN¥343.97 Million ≈ $50.33 Million |
-46.53% |
| 2013-12-31 | CN¥643.30 Million ≈ $94.14 Million |
-20.66% |
| 2012-12-31 | CN¥810.78 Million ≈ $118.64 Million |
+3.17% |
| 2011-12-31 | CN¥785.85 Million ≈ $114.99 Million |
+8.09% |
| 2010-12-31 | CN¥727.00 Million ≈ $106.38 Million |
+521.87% |
| 2009-12-31 | CN¥116.90 Million ≈ $17.11 Million |
+43.35% |
| 2008-12-31 | CN¥81.55 Million ≈ $11.93 Million |
+8.90% |
| 2007-12-31 | CN¥74.89 Million ≈ $10.96 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to INKON Life Technology Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 277.6% over the analyzed period, indicating profitable operations and earnings retention.
INKON Life Technology Co Ltd Net Assets Breakdown (December 2025)
INKON Life Technology Co Ltd net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥70.29 Million | 2.80% |
| Other Components | CN¥2.44 Billion | 97.20% |
| Total Equity | CN¥2.51 Billion | 100.00% |
INKON Life Technology Co Ltd Competitors by Market Cap
The table below lists competitors of INKON Life Technology Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Turk Tuborg Bira ve Malt Sanayi AS
IS:TBORG
|
$810.46 Million |
|
Tourism Finance Corporation of India Limited
NSE:TFCILTD
|
$810.57 Million |
|
Zhejiang Great Southeast Co Ltd
SHE:002263
|
$810.85 Million |
|
Dexterra Group Inc
TO:DXT
|
$810.98 Million |
|
Republic Airways Holdings Inc
NASDAQ:RJET
|
$810.45 Million |
|
Clevo Co
TW:2362
|
$810.35 Million |
|
Genus Power Infrastructures Limited
NSE:GENUSPOWER
|
$810.35 Million |
|
InMode Ltd
NASDAQ:INMD
|
$810.22 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in INKON Life Technology Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,430,580,107 to 2,512,326,194, a change of 81,746,087 (3.4%).
- Net income of 68,540,725 contributed positively to equity growth.
- Dividend payments of 10,475,126 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥68.54 Million | +2.73% |
| Dividends Paid | CN¥10.48 Million | -0.42% |
| Other Changes | CN¥23.68 Million | +0.94% |
| Total Change | CN¥- | 3.36% |
Book Value vs Market Value Analysis
This analysis compares INKON Life Technology Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.20x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 1.70x to 2.20x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | CN¥4.34 | CN¥7.39 | x |
| 2018-12-31 | CN¥3.73 | CN¥7.39 | x |
| 2019-12-31 | CN¥2.45 | CN¥7.39 | x |
| 2020-12-31 | CN¥3.44 | CN¥7.39 | x |
| 2021-12-31 | CN¥2.76 | CN¥7.39 | x |
| 2022-12-31 | CN¥2.00 | CN¥7.39 | x |
| 2023-12-31 | CN¥2.15 | CN¥7.39 | x |
| 2024-12-31 | CN¥3.24 | CN¥7.39 | x |
| 2025-12-31 | CN¥3.35 | CN¥7.39 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently INKON Life Technology Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.73%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 3.64%
- • Asset Turnover: 0.45x
- • Equity Multiplier: 1.67x
- Recent ROE (2.73%) is above the historical average (-1.72%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | 13.27% | 16.43% | 0.43x | 1.87x | CN¥2.45 Million |
| 2008 | 14.06% | 15.51% | 0.45x | 2.01x | CN¥3.31 Million |
| 2009 | 17.41% | 21.25% | 0.43x | 1.92x | CN¥8.66 Million |
| 2010 | 5.81% | 25.13% | 0.20x | 1.17x | CN¥-30.50 Million |
| 2011 | 7.49% | 28.35% | 0.25x | 1.06x | CN¥-19.73 Million |
| 2012 | 0.85% | 2.62% | 0.25x | 1.31x | CN¥-69.79 Million |
| 2015 | 0.73% | 3.78% | 0.15x | 1.28x | CN¥-133.62 Million |
| 2016 | 2.55% | 12.74% | 0.17x | 1.17x | CN¥-160.97 Million |
| 2017 | 5.15% | 37.18% | 0.13x | 1.10x | CN¥-115.36 Million |
| 2018 | 2.46% | 9.95% | 0.19x | 1.28x | CN¥-153.95 Million |
| 2019 | -52.56% | -122.77% | 0.29x | 1.46x | CN¥-837.25 Million |
| 2020 | 5.80% | 19.38% | 0.25x | 1.20x | CN¥-92.92 Million |
| 2021 | -20.53% | -33.41% | 0.44x | 1.39x | CN¥-541.44 Million |
| 2022 | -46.44% | -51.54% | 0.57x | 1.58x | CN¥-724.23 Million |
| 2023 | 7.27% | 6.83% | 0.61x | 1.74x | CN¥-37.73 Million |
| 2024 | 4.75% | 7.40% | 0.44x | 1.46x | CN¥-127.63 Million |
| 2025 | 2.73% | 3.64% | 0.45x | 1.67x | CN¥-182.69 Million |
Industry Comparison
This section compares INKON Life Technology Co Ltd's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $1,879,885,199
- Average return on equity (ROE) among peers: 23.65%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| INKON Life Technology Co Ltd (300143) | CN¥2.65 Billion | 13.27% | 0.57x | $810.45 Million |
| Shanghai Kehua Bio-Engineering Co Ltd (002022) | $2.08 Billion | 10.47% | 0.31x | $387.62 Million |
| Jiangsu Yuyue Medical Equipment & Supply Co Ltd (002223) | $482.51 Million | 20.84% | 0.32x | $4.19 Billion |
| Double Medical Technology Inc (002901) | $274.36 Million | 50.77% | 0.99x | $2.51 Billion |
| Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) | $115.39 Million | 30.85% | 0.16x | $490.64 Million |
| Lepu Medical Tech Beijing (300003) | $12.27 Billion | 14.01% | 0.69x | $3.36 Billion |
| Edan Instruments Inc (300206) | $1.16 Billion | 1.16% | 0.17x | $993.28 Million |
| Guangdong Biolight Meditech Co Ltd (300246) | $354.32 Million | 9.53% | 0.12x | $483.51 Million |
| Beijing Leadman Biochemistry Co Ltd (300289) | $159.72 Million | 34.06% | 0.62x | $468.88 Million |
| Sinocare Inc (300298) | $17.42 Million | 41.15% | 0.68x | $1.54 Billion |
About INKON Life Technology Co Ltd
INKON Life Technology Co., Ltd. focuses on building an ecosystem platform for providing medical services for tumors in China and internationally. It provides medical devices solutions for radiotherapy, life support, image enhancement, and chronic disease treatment; and oncology medical services, as well as equipment for cancer prevention, diagnosis, treatment, and rehabilitation. The company was … Read more